Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 3/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6962727 | 1.00 | UCHL1 (0.52) | UCHL1USP30ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL20164038 | 0.96 | UCHL1 (0.48) | UCHL1USP30ALDH1A1KMT2A | |
| SCHEMBL20164037 | 0.96 | UCHL1 (0.48) | UCHL1USP30ALDH1A1KMT2A | |
| SCHEMBL31226242 | 0.87 | USP30 (0.43) | UCHL1USP30ALDH1A1KMT2ATSHR | |
| SCHEMBL18878228 | 0.85 | RIPK1 (0.49) | ALDH1A1RIPK1 | |
| SCHEMBL18606763 | 0.85 | RIPK1 (0.49) | ALDH1A1RIPK1 | |
| SCHEMBL31226659 | 0.85 | ALDH1A1 (0.44) | UCHL1USP30ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL31226999 | 0.85 | ALDH1A1 (0.44) | UCHL1USP30ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL3667865 | 0.84 | USP30 (0.51) | UCHL1USP30ALDH1A1KMT2ATSHR | |
| SCHEMBL31226629 | 0.84 | USP30 (0.41) | UCHL1USP30ALDH1A1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-07-18 | — | — | US | disclosed |
| US-8445684-B2 | Nicotinic acetylcholine receptor ligands and the uses thereof | PsycoGenics Inc. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | CHRNG, CHRNA5, CHRNA2 | UCHL1 2815/4885USP30 2345/4885ALDH1A1 1052/4885 |
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | CHRNG, CHRNA5, CHRNA2 | UCHL1 2815/4885USP30 2345/4885ALDH1A1 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.